Biotech, Muscular Dystrophy, deals
AVI Wins Part of $2.5M Contract
Luke Timmerman 5/6/09
AVI Biopharma, the Portland, OR-based developer of RNA-based therapies, said today it has been awarded part of a $2.5 million contract from the U.S. Department of Defense to develop a drug for Duchenne Muscular Dystrophy. The contract, awarded to researchers at the Children’s National Medical Center in Washington D.C., will support animal studies to develop AVI-4658. AVI (NASDAQ: AVII) will serve as a subcontractor, the company said.
Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.
